Postoperative Adjuvant Chemotherapy and Chemoradiation for Rectal Cancer

직장암의 근치적 절제술 후 보조 화학요법과 보조 화학방사선 병용요법

  • Lee Kang Kyoo (Department of Radiation Oncology, Wonju Christian Hospital, Yonsei University Wonju College of Medicine) ;
  • Park Kyung Ran (Department of Radiation Oncology, Wonju Christian Hospital, Yonsei University Wonju College of Medicine) ;
  • Lee Ik Jae (Department of Radiation Oncology, Wonju Christian Hospital, Yonsei University Wonju College of Medicine) ;
  • Kim Ik Yong (Department of General Surgery, Wonju Christian Hospital, Yonsei University Wonju College of Medicine) ;
  • Sim Kwang Yong (Department of Medical Oncology, Wonju Christian Hospital, Yonsei University Wonju College of Medicine) ;
  • Kim Dae Sung (Department of General Surgery, Wonju Christian Hospital, Yonsei University Wonju College of Medicine) ;
  • Lee Jong Young (Department of Radiation Oncology, Wonju Christian Hospital, Yonsei University Wonju College of Medicine)
  • 이강규 (연세대학교 원주의과대학 방사선종양학교실) ;
  • 박경란 (연세대학교 원주의과대학 방사선종양학교실) ;
  • 이익재 (연세대학교 원주의과대학 방사선종양학교실) ;
  • 김익용 (연세대학교 원주의과대학 일반외과학교실) ;
  • 심광용 (연세대학교 원주의과대학 종양내과학교실) ;
  • 김대성 (연세대학교 원주의과대학 일반외과학교실) ;
  • 이종영 (연세대학교 원주의과대학 방사선종양학교실)
  • Published : 2002.12.01

Abstract

Purpose : The aim of this study was to determine if postoperative adjuvant chemotherapy (CT) alone and concurrent chemoradiation (CCRT), following radical surgery, improved the disease free survival (DFS) and overall survival (OS) in rectal cancer AJCC stage II and III patients. Materials and Methods : A total of 144 patients with AJCC stage II and III rectal cancer who had had radical surgery between 1989 and 1999 were included in the study. Of these patients, 72 had been treated with postoperative CT, and the other 72 with postoperative CCRT. The chemotherapy regimen consisted of oral UFT on a daily basis for $1\~12$ months (median 12 months) or 5-FU ($500\;mg/m^2$ for 5 days) intravenous (IV) chemotherapy with 4 week intervals for $1\~18$ cycles (median 6 cycles). Radiation of 4,500 cGy was delivered to the surgical bed and regional pelvic lymph nodes area, followed by $540\~1,440\;cGy$ (median 540 cGy) boost to the surgical bed. The follow-up period ranged from 20 to 150 months, with a median of 44 months. Results : The 5-year OS was $60.9\%\;and\;68.9\%$ (p=0.0915), and the 5-year DFS was $56.1\%\;and\;63.8\%$ (p=0.3510) for postoperative CT and postoperative CCRT, respectively. In the stage nm patients, the 5-year OS was $71.1\%\;and\;92.2\%$, and the 5-year DFS was $57.3\%\;and\;85.4\%$ for postoperative CT and CCRT, respectively. The OS was significantly improved (p=0.0379) but the DFS was not with postoperative CCRT compared to the postoperative CT (p=0.1482). In the stage III patients, the 5-year OS was $52.0\%\;and\;55.0\%$, and the 5-year DFS was $47.8\%\;and\;49.8\%$ for postoperative CT and postoperative CCRT. There were no statistically significant differences between postoperative CT and CCRT (p=0.4280 and p=0.7891) in OS and DFS. The locoregional relapses were $16.7\%\;and\;12.5\%$ for postoperative CT and CCRT, respectively. The distant relapses were $25.0\%\;and\;26.4\%$ for postoperative CT and CCRT, respectively. Conclusion : These results showed that postoperative CCRT compared with CT alone improved OS in stage II patients. Although there was no statistical significance, the addition of postoperative RT to CT reduced locoregional relapses compared to CT alone.

목적 : 본 연구는 AJCC 병기 II기와 III기의 국소진행성 직장암으로 근치적 절제술을 받은 환자들을 대상으로 각 병기에서 보조 화학요법 단독에 비해 화학방사선 병행요법이 생존율 및 무병생존율을 향상시키는지에 대하여 알아보고자 하였다. 대상 및 방법 : 1989년 1월부터 1999년 12월까지 AJCC 병기 II기와 III기의 직장암으로 근치적 절제술이 시행된 144명을 대상으로 하였다. 그 중 보조 치료방법에 따라 분류를 하면 화학요법 단독군이 72명이었고, 화학방사선 병행요법군은 72명이었다. 화학요법은 수술 후 UFT를 매일 경구복용하거나(중앙값 12개월) 5-FU를 기초로 한 항암제를 4주 간격으로 정맥주사하였고, 투여기간은 $1\~18$차례(중앙값 6차례)이였다. 방사선치료는 직장과 골반 내 영역 림프절 영역에 4,500 cGy를 조사한 후 수술 부위에 $540\~1,440\;cGy$ (중앙값 540 cGy) 추가조사를 시행하였다. 추적관찰 기간은 $20\~150$개월로 중앙값은 44개월이었다. 결과 : 5년 생존율은 화학요법 단독군과 화학방사선 병행요법군에서 각각 $60.9\%$$68.9\%$ (p=0.0915)였고, 5년 무병생존율은 각각 $56.1\%$$63.8\%$ (p=0.3510)로 두 군사이에 유의한 차이를 보이지 않았다. 병기별로 분석하였을 때 II기에서의 5년 생존율은 화학요법 단독군이 $71.1\%$, 화학방사선 병행요법군은 $92.2\%$로 두 군간에 통계적으로 유의한 차이를 보였으나(p=0.0379), 5년 무병생존율에서는 화학요법 단독군이 $57.3\%$, 화학방사선 병행요법군은 $85.4\%$로 두군간에 통계적으로 유의한 차이를 보이지 않았다(p=0.1482). III기에서는 5년 생존율과 무병생존율이 화학요법 단독군에서는 $52.0\%$$47.8\%$였고, 화학방사선 병행요법군에서는 $55.0\%$$49.8\%$로 두 군 사이에는 유의한 차이를 보이지 않았다(p=0.4280, p=0.7891). 국소재발율은 화학요법 단독군이 $16.7\%$, 화학방사선 병행요법군은 $12.5\%$였고, 원격재발율은 화학요법 단독군이 $25.0\%$, 화학방사선 병행요법군은 $26.4\%$였다. 결론 : 본 연구에서는 II기에서 보조 화학요법에 방사선치료를 병행함으로써 보조 화학요법 단독 치료시와 비교하여 생존율의 유의한 증가를 보였고, 비록 통계적으로 유의한 차이를 보이지는 못했지만 국소재발율의 감소를 보였다.

Keywords

References

  1. Rich T, Gunderson LL, Lew R, et aI. Patterns of recurrence of rectal cancer after potentially curative aurgery. Cancer 1983;52:1317-1329 https://doi.org/10.1002/1097-0142(19831001)52:7<1317::AID-CNCR2820520731>3.0.CO;2-6
  2. PiIipshen SJ, HeIweiI M, Quan SHQ, Sternberg SS, Enker WE. Patterns of pelvic recurrence following definitive resection of rectal cancer. Cancer 1984;53:1354-1362 https://doi.org/10.1002/1097-0142(19840315)53:6<1354::AID-CNCR2820530623>3.0.CO;2-J
  3. BrizeI HE, Tepperman BS. Postoperative adjuvant irradiation for adenocarcinoma of the rectum and sigmoid. Am J CIin Oncol 1984;7(6):679-685 https://doi.org/10.1097/00000421-198412000-00016
  4. Ghossein NA, SamaIa EC, AIpert S, et aI. Elective postoperative radiotherapy after incomplete resection of coIorectal cancer. Dis Colon Rectum 1981;24:252-256 https://doi.org/10.1007/BF02641870
  5. Hoskins RB, Gunderson LL, Dosoretz DE, et aI. Adjuvant postoperative radiotherapy in carcinoma of the rectum and rectosigmoid. Cancer 1985;55:61-71 https://doi.org/10.1002/1097-0142(19850101)55:1<61::AID-CNCR2820550111>3.0.CO;2-Z
  6. GastrointestinaI Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Eng J Med 1985;312:1465-1472 https://doi.org/10.1056/NEJM198506063122301
  7. CoIorectaI Cancer CoIIaborative Group. Agjuvant radiotherapy for rectal cancer: a systemic overview of 8507 patients from 22 randomised trials. Lancet 2001;358:1291-1304 https://doi.org/10.1016/S0140-6736(01)06409-1
  8. Treurniet-Donker AD, Putten WL, WereIdsma Jc, et aI. Postoperative radiation therapy for rectal cancer: An interim analysis of a prospective, randomized muIticenter trial in the NetherIands. Cancer 1991;67:2042-2048 https://doi.org/10.1002/1097-0142(19910415)67:8<2042::AID-CNCR2820670806>3.0.CO;2-4
  9. Arnaud JP, NordIinger B, Bosset JF, et aI. Radical surgery and postoperative radiotherapy as combined treatment in rectal cancer. Final resuIts of a phase III study of the European Organization for Research and Treatment of Cancer. Br J Surg 1997;84:352-357
  10. Tveit KM, Hagen GS, Trondsen E, et aI. Randomized controIIed trial of postoperative radiotherapy and short-term time-scheduIed 5-fIuorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Br J Surg 1997;84:1130-1135 https://doi.org/10.1002/bjs.1800840827
  11. Fisher B, WoImark N, Rockette H. et aI. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP Protocol R-01. J Natl Cancer Inst 1988;80:21-29
  12. Hafstrom L, DomeIIof L, Rudenstam CM, et aI. Adjuvant chemotherapy with 5-fIuorouracil, vincristine and CCNU for patients with Dukes' C colorectal cancer. The Swedish GastrointestinaI Tumour Adjuvant Therapy Group. Br J Surg 1990;77:1345-1348
  13. Krook JE, MoerteI CG, Gunderson LL, et aI. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Eng J Med 1991;324:709-715 https://doi.org/10.1056/NEJM199103143241101
  14. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-1450 https://doi.org/10.1001/jama.264.11.1444
  15. WoImark N, Wieand S, Hyams CM, et aI. Randomized trial of postoperative adjuvnat chemotherapy of the rectum: Nationas Surgical Adjuvnat Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 2000;92:388-96
  16. MedicaI Research CounciI RectaI Working Party. Randomised trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum. Lancet 1996;348:1610-1614 https://doi.org/10.1016/S0140-6736(96)05349-4
  17. Cafiero F, Gipponi M, Peressini A, et aI. Preliminary analysis of a radomized clinical of aajuvant postoperative RT Vs. postoperative RT pIus 5-FU and Ievamisole in patients with TNM stage II-III resectabIe rectal cancer. J Surg Oncol 2000;75:80-88
  18. GastrointestinaI Tumor Study Group. Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J CIin Oncol 1992;10:549-557
  19. O'ConneII MJ, Martenson JA, Wieand HS, et aI. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fIuorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502-507 https://doi.org/10.1056/NEJM199408253310803
  20. Tepper JE, O'ConneII MJ, Petroni GR, et aI. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of Intergroup 0114. J Clin Oncol 1997;15:2030-2039
  21. Pazdur R, DouiIIard, SkiIIings JR, et aI. Multicenter phase III trial of 5-fluorouracil (5-FU) or UFTTM in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999;18:263a
  22. ChamichaeI J, PopieIa T, Radstone D, et aI. Randomized comparative study of ORZEL (oral uracil/tegafur (UFTTM) plus leucovorin (LV) versus parenteral 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer. Proc Am Soc CIin Oncol 1999;18:264a
  23. Kato T, Ohashi Y, Nakazato H, et aI. Efficacy of oral UFT as sdjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. Langenbecks Arch Surg 2002; 386:575-581 https://doi.org/10.1007/s00423-002-0278-x
  24. Liu G, Franseen E, Fitch MI, et aI. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115
  25. Hoff PM, Batist G, Cox J, et aI. Comparison of oral capecitabine versus intravenous fluorouracil plus Ieucovorin as first-Iine treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292
  26. Cutsem EV, TweIves C, Cassidy J, et aI. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastaic colorectal cencer: results of a large phase III study. J Clin Oncol 2001;19:4097-4106